⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XENE News
Xenon Pharmaceuticals Inc
Form 8-K
sec.gov
XENE
Form 8-K
sec.gov
XENE
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
globenewswire.com
XENE
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
globenewswire.com
XENE
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
globenewswire.com
XENE
Xenon Pharmaceuticals Announces Proposed Public Offering
globenewswire.com
XENE
Xenon Pharmaceuticals Announces Proposed Public Offering
globenewswire.com
XENE
Form 8-K
sec.gov
XENE
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
globenewswire.com
XENE
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
globenewswire.com
XENE